{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:53:46Z","timestamp":1769151226043,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The safety of COVID-19 vaccines has been clarified in clinical trials; however, some immunocompromised patients, such as myasthenia gravis (MG) patients, are still hesitant to receive vaccines. Whether COVID-19 vaccination increases the risk of disease worsening in these patients remains unknown. This study aims to evaluate the risk of disease exacerbation in COVID-19-vaccinated MG patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data in this study were collected from the MG database at Tangdu Hospital, the Fourth Military Medical University, and the Tertiary Referral Diagnostic Center at Huashan Hospital, Fudan University, from 1 April 2022 to 31 October 2022.\u00a0A self-controlled case series method was applied, and the incidence rate ratios were calculated in the prespecified risk period using conditional Poisson regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Inactivated COVID-19 vaccines did not increase the risk of disease exacerbation in MG patients with stable disease status. A few patients experienced transient disease worsening, but the symptoms were mild. It is noted that more attention should be paid to thymoma-related MG, especially within 1 week after COVID-19 vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>COVID-19 vaccination has no long-term impact on MG relapse.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1141983","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:56:06Z","timestamp":1683521766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhe","family":"Ruan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Lan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Dong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Lin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Jia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Shan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.847873","article-title":"Factors affecting the intention of covid-19 vaccination in Korean patients with myasthenia gravis: a survey-based study","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15368","article-title":"Covid-19 vaccination hesitancy among people with chronic neurological disorders: a position paper","volume":"29","author":"Rakusa","year":"2022","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"Covid-19 vaccine Bnt162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-Covid-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10780-7","article-title":"Covid-19 mrna vaccination leading to cns inflammation: a case series","volume":"269","author":"Khayat-Khoei","year":"2022","journal-title":"J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following Mrna\/DNA sars-Cov-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15348","article-title":"Safety and tolerability of sars-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience","volume":"29","author":"Farina","year":"2022","journal-title":"Eur J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11303-8","article-title":"Bnt162b2 mrna covid-19 vaccine three-dose safety and risk of covid-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves","volume":"269","author":"Doron","year":"2022","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101112","article-title":"Covid-19 vaccination in patients with myasthenia gravis: a single-center case series","volume":"9","author":"Ruan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923017","article-title":"Safety of inactivated sars-Cov-2 vaccines in myasthenia gravis: a survey-based study","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from Diphtheria\/Tetanus\/Pertussis and Measles\/Mumps\/Rubella vaccines","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a008695","article-title":"Case series analysis of adverse reactions to vaccines: a comparative evaluation","volume":"143","author":"Farrington","year":"1996","journal-title":"Am J Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"Bmj"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2477","article-title":"Sample sizes for self-controlled case series studies","volume":"25","author":"Musonda","year":"2006","journal-title":"Stat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12967-021-02961-9","article-title":"Nomogram for short-term outcome assessment in achr subtype generalized myasthenia gravis","volume":"19","author":"Zhao","year":"2021","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.790941","article-title":"Comorbid autoimmune diseases in patients with myasthenia gravis: a retrospective cross-sectional study of a Chinese cohort","volume":"12","author":"Shi","year":"2021","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895007","article-title":"Development and validation of a nomogram for predicting generalization in patients with ocular myasthenia gravis","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01129-z","article-title":"Thymectomy and risk of generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study","volume":"18","author":"Li","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-021-00292-x","article-title":"Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study","volume":"11","author":"Guo","year":"2022","journal-title":"Neurol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15292","article-title":"Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis","volume":"29","author":"Ruan","year":"2022","journal-title":"Eur J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of Bnt162b2 mrna covid-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00146-3","article-title":"Covid-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the Zoe covid study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120225","article-title":"Flare of myasthenia gravis induced by covid-19 vaccines","volume":"436","author":"Ishizuchi","year":"2022","journal-title":"J Neurol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00255.x","article-title":"The effect of age on the cognate function of Cd4+ T cells","volume":"205","author":"Haynes","year":"2005","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1141983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:56:07Z","timestamp":1683521767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1141983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2023.1141983"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1141983","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"article-number":"1141983"}}